Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP393954.RAvMXisqz2MkoANIVJGYklNY57KD_laBbDK7Ef6-BuW18130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP393954.RAvMXisqz2MkoANIVJGYklNY57KD_laBbDK7Ef6-BuW18130_assertion type Assertion NP393954.RAvMXisqz2MkoANIVJGYklNY57KD_laBbDK7Ef6-BuW18130_head.
- NP393954.RAvMXisqz2MkoANIVJGYklNY57KD_laBbDK7Ef6-BuW18130_assertion wasGeneratedBy ECO_0000203 NP393954.RAvMXisqz2MkoANIVJGYklNY57KD_laBbDK7Ef6-BuW18130_provenance.
- NP393954.RAvMXisqz2MkoANIVJGYklNY57KD_laBbDK7Ef6-BuW18130_assertion wasDerivedFrom befree-20140225 NP393954.RAvMXisqz2MkoANIVJGYklNY57KD_laBbDK7Ef6-BuW18130_provenance.
- NP393954.RAvMXisqz2MkoANIVJGYklNY57KD_laBbDK7Ef6-BuW18130_assertion SIO_000772 21898529 NP393954.RAvMXisqz2MkoANIVJGYklNY57KD_laBbDK7Ef6-BuW18130_provenance.
- NP393954.RAvMXisqz2MkoANIVJGYklNY57KD_laBbDK7Ef6-BuW18130_assertion evidence source_evidence_literature NP393954.RAvMXisqz2MkoANIVJGYklNY57KD_laBbDK7Ef6-BuW18130_provenance.
- NP393954.RAvMXisqz2MkoANIVJGYklNY57KD_laBbDK7Ef6-BuW18130_assertion description "[Therefore, we propose that CTA-specific immunotherapy for AML should preferentially target PRAME and/or should be combined with the application of demethylating agents opening the perspective for alternative targets like CTA SSX-2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP393954.RAvMXisqz2MkoANIVJGYklNY57KD_laBbDK7Ef6-BuW18130_provenance.